Top

Published in:

01-01-2019 | Opinion Paper

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

Authors: Michele Maio, George Coukos, Soldano Ferrone, Bernard A. Fox, Wolf H. Fridman, Patrick L. Garcia, Michael Lahn, Olivier Provendier, Vincenzo Russo, Dominik Rüttinger, Aiman Shalabi, Zlatko Trajanoski, Jean Viallet, Jedd D. Wolchok, Ramy Ibrahim

Published in: Cancer Immunology, Immunotherapy | Issue 1/2019

Abstract

A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.

Maio M, Fonsatti E (2014) The Italian network for tumor biotherapy (NIBIT): past, present and future goals. Rev Health Care 5(1):3–6CrossRef

Russo V, Amadori A, Bregni M, Calabro L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M (2017) Goals and objectives of the Italian network for tumor biotherapy (NIBIT). Cytokine Growth Factor Rev 36:1–3. https://doi.org/10.1016/j.cytogfr.2017.06.004 CrossRefPubMed

Maio M, Lofiego MF, Fazio C, Cannito S, Chiarucci C, Giacobini G, Valente M, Tunici P, Covre A, Russo V (2018) Fifteenth meeting of the network Italiano per la Bioterapia dei Tumori (NIBIT) on cancer bio-immunotherapy, Siena, Italy, October 5–7, 2017. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-018-2222-0 CrossRefPubMed

Hansen AR, Infante JR, McArthur G, Gordon MS, Lesokhin AM, Stayner A-L, Bauer TM, Sandhu S, Tsai F, Snyder A, Subramaniam DS, Kim J, Stefanich E, Li C-C, Ruppel J, Anderson M, Gilbert H, McCall B, Huseni MA, Rhee I, Pishvaian M (2016) Abstract CT097: a first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors. Cancer Res 76(14 Supplement):CT097–CT097. https://doi.org/10.1158/1538-7445.am2016-ct097 CrossRef

Angevin E, Bauer TM, Ellis CE, Gan H, Hall R, Hansen A, Hoos A, Jewell RC, Katz J, Martin-Liberal J, Maio M, Mayes PA, Mazumdar J, Millward M, Rischin D, Schellens JH, Yadavilli S, Zhou H (2017) Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Res 77(13 Supplement):CT039–CT039. https://doi.org/10.1158/1538-7445.am2017-ct039 CrossRef

Sullivan RJ, Gonzalez R, Lewis KD, Hamid O, Infante JR, Patel MR, Hodi FS, Wallin J, Pitcher B, Cha E, Roberts L, Ballinger M, Hwu P (2017) Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): updated safety and clinical activity. J Clin Oncol 35(15_suppl):3063–3063. https://doi.org/10.1200/JCO.2017.35.15_suppl.3063 CrossRef

McDermott DF, Atkins MB, Motzer RJ, Rini BI, Escudier BJ, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth JD, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Choi Y, Huseni MA, Fine GD, Powles T (2017) A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 35(6_suppl):431–431. https://doi.org/10.1200/JCO.2017.35.6_suppl.431 CrossRef

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee J-L, Hawkins RE, Ravaud A, Alekseev BY, Staehler MD, Uemura M, Donaldson F, Li S, Huseni MA, Schiff C, Rini BI (2018) IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 36(6_suppl):578–578. https://doi.org/10.1200/JCO.2018.36.6_suppl.578 CrossRef

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A (2016) Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 52:50–66. https://doi.org/10.1016/j.ejca.2015.08.021 CrossRefPubMed

10.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73(24):7189–7198. https://doi.org/10.1158/0008-5472.CAN-12-4174 CrossRefPubMedPubMedCentral

11.

Dempke WCM, Fenchel K, Uciechowski P, Dale SP (2017) Second- and third-generation drugs for immuno-oncology treatment-the more the better? Eur J Cancer 74:55–72. https://doi.org/10.1016/j.ejca.2017.01.001 CrossRefPubMed

12.

Zappasodi R, Li Y, Abu-Akeel M, Qi J, Wong P, Sirard C, Postow M, Schaer DA, Newman W, Koon H, Velcheti V, Callahan MK, Wolchok JD, Merghoub T (2017) Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial. Cancer Res 77(13 Supplement):CT018–CT018. https://doi.org/10.1158/1538-7445.am2017-ct018 CrossRef

13.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA (2017) Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res 23(20):6165–6177. https://doi.org/10.1158/1078-0432.CCR-16-2677 CrossRefPubMedPubMedCentral

14.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN (2017) Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res 5(9):755–766. https://doi.org/10.1158/2326-6066.CIR-17-0292 CrossRefPubMed

15.

Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ (2016) Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci USA 113(11):E1555–E1564. https://doi.org/10.1073/pnas.1521812113 CrossRefPubMedPubMedCentral

16.

Hulett TW, Jensen SM, Wilmarth PA, Reddy AP, Ballesteros-Merino C, Afentoulis ME, Dubay C, David LL, Fox BA (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6(1):27. https://doi.org/10.1186/s40425-018-0331-0 CrossRefPubMedPubMedCentral

17.

Persson N, Jansson B, Stuhr-Hansen N, Kovacs A, Welinder C, Danielsson L, Blixt O (2016) A combinatory antibody-antigen microarray assay for high-content screening of single-chain fragment variable clones from recombinant libraries. PLoS One 11(12):e0168761. https://doi.org/10.1371/journal.pone.0168761 CrossRefPubMedPubMedCentral

18.

Stuchly J, Kanderova V, Fiser K, Cerna D, Holm A, Wu W, Hrusak O, Lund-Johansen F, Kalina T (2012) An automated analysis of highly complex flow cytometry-based proteomic data. Cytometry A 81(2):120–129. https://doi.org/10.1002/cyto.a.22011 CrossRefPubMed

19.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA (2016) Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer 4:3. https://doi.org/10.1186/s40425-016-0107-3 CrossRefPubMedPubMedCentral

20.

Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37(5):508–516. https://doi.org/10.1053/j.seminoncol.2010.09.008 CrossRefPubMed

21.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R (2017) Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res 23(8):1929–1936. https://doi.org/10.1158/1078-0432.CCR-16-1272 CrossRefPubMed

22.

Chester C, Sanmamed MF, Wang J, Melero I (2018) Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood 131(1):49–57. https://doi.org/10.1182/blood-2017-06-741041 CrossRefPubMed

23.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE (2017) Report on the third FDA-AACR oncology dose-finding workshop. Cancer Immunol Res 5(12):1058–1061. https://doi.org/10.1158/2326-6066.CIR-17-0590 CrossRefPubMed

24.

Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731–2738CrossRefPubMed

25.

Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinska E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Maelandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 17(4):254–268. https://doi.org/10.1038/nrc.2016.140 CrossRefPubMed

26.

Rosenberg SA (2015) CCR 20th anniversary commentary: autologous T Cells-the ultimate personalized drug for the immunotherapy of human cancer. Clin Cancer Res 21(24):5409–5411. https://doi.org/10.1158/1078-0432.CCR-14-3131 CrossRefPubMedPubMedCentral

27.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213. https://doi.org/10.1056/NEJMoa020177 CrossRefPubMed

28.

Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124(2):192–198. https://doi.org/10.1016/j.ygyno.2011.09.039 CrossRefPubMed

29.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19(17):4801–4815. https://doi.org/10.1158/1078-0432.CCR-13-1185 CrossRefPubMedPubMedCentral

30.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G (2015) The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28-costimulated T cells prepared for adoptive therapy. Clin Cancer Res 21(12):2840–2850. https://doi.org/10.1158/1078-0432.CCR-14-2777 CrossRefPubMedPubMedCentral

31.

Bassani-Sternberg M, Coukos G (2016) Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr Opin Immunol 41:9–17. https://doi.org/10.1016/j.coi.2016.04.005 CrossRefPubMed

32.

Muller M, Gfeller D, Coukos G, Bassani-Sternberg M (2017) ‘Hotspots’ of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front Immunol 8:1367. https://doi.org/10.3389/fimmu.2017.01367 CrossRefPubMedPubMedCentral

33.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA (2017) The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med 15(1):223. https://doi.org/10.1186/s12967-017-1325-2 CrossRefPubMedPubMedCentral

34.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B (2017) Systematic evaluation of immune regulation and modulation. J Immunother Cancer 5:21. https://doi.org/10.1186/s40425-017-0223-8 CrossRefPubMedPubMedCentral

35.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 5:44. https://doi.org/10.1186/s40425-017-0243-4 CrossRefPubMedPubMedCentral

36.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ (2017) Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer 117(7):913–920. https://doi.org/10.1038/bjc.2017.274 CrossRefPubMedPubMedCentral

37.

Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, Pawelec G, Garbe C, Weide B (2016) Increases in absolute lymphocytes and circulating CD4 + and CD8 + T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res 22(19):4848–4858. https://doi.org/10.1158/1078-0432.CCR-16-0249 CrossRefPubMedPubMedCentral

38.

Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22(12):2908–2918. https://doi.org/10.1158/1078-0432.CCR-15-2412 CrossRefPubMedPubMedCentral

39.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kahler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22(22):5487–5496. https://doi.org/10.1158/1078-0432.CCR-16-0127 CrossRefPubMedPubMedCentral

40.

Shreders A, Joseph RW, Johnson DB, Peng C, Puzanov I, Dronca RS, Bryce AH, Markovic S, Kottschade LA, Sosman JA (2015) Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors. J Clin Oncol 33(15_suppl):e20045–e20045. https://doi.org/10.1200/jco.2015.33.15_suppl.e20045 CrossRef

41.

Larkin JFP, Gonzalez R, Thomas L, Maio M, Hill A, Postow M, Savage K, Hassel J, Corrie P, Wagstaff J, Mortier L, Schadendorf D, Hamid O, Long GV, Marquez I, Rutkowski P, Walker D, Bhore R, Chiarion-Sileni V, Hogg D (2016) Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma and elevated serum lactate dehydrogenase: a pooled analysis. Paper presented at the Society for Melanoma Research Boston, MA, US, 6–9 November 2016

42.

Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M, Wu H, McCausland M, Chen Z, Zhang C, Khuri FR, Owonikoko TK, Ahmed R, Ramalingam SS (2017) Proliferation of PD-1 + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA 114(19):4993–4998. https://doi.org/10.1073/pnas.1705327114 CrossRefPubMedPubMedCentral

43.

Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM (2016) Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 5(4):e1100788. https://doi.org/10.1080/2162402X.2015.1100788 CrossRefPubMed

44.

Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J, Manos M, Eastman LM, Maecker HT, Hodi FS (2018) Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer 6(1):18. https://doi.org/10.1186/s40425-018-0328-8 CrossRefPubMedPubMedCentral

45.

Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, Fanucchi M, Lim SH (2018) Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-018-2192-2 CrossRefPubMed

46.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D’Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545(7652):60–65. https://doi.org/10.1038/nature22079 CrossRefPubMedPubMedCentral

47.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML (2011) Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 17(10):3064–3076. https://doi.org/10.1158/1078-0432.CCR-10-2234 CrossRefPubMedPubMedCentral

Title: Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
Authors: Michele Maio
George Coukos
Soldano Ferrone
Bernard A. Fox
Wolf H. Fridman
Patrick L. Garcia
Michael Lahn
Olivier Provendier
Vincenzo Russo
Dominik Rüttinger
Aiman Shalabi
Zlatko Trajanoski
Jean Viallet
Jedd D. Wolchok
Ramy Ibrahim
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 1/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2285-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression

Fighting breast cancer stem cells through the immune-targeting of the xCT cystine–glutamate antiporter

Prediction of neoepitopes from murine sequencing data

Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology

Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer